Ovarian cancer: use of multiple modality programs involving surgery, radiation therapy and chemotherapy.
Publication/Presentation Date
7-1-1977
Abstract
Appreciating the past reports of effectiveness for various therapeutic modalities in ovarian cancer, the Gynecologic Oncology Group activated eight protocols. Three involved epithelial lesions with randomized multimodality trials alone or in combination. The other protocols were devoted to registration of rare tumor case reports. Conclusions are still difficult to reach due to inconsistencies in pathologic diagnoses and deficiencies in radiation therapy, chemotherapy and surgery inherent in the initial phases of group development by diverse specialist in oncology. Adjuvant therapy for early cancer seems to have no advantage. Single drug, melphalan therapy may be as effective as multi-drug, irradiation or combined drug-irradiation therapy and less toxic. For the rare tumors, preliminary results suggest therapeutic advantage for at least one triple drug program in malignant teratoma. With the lessons of the past, it is anticipated that new studies briefly described herewith may be more effectively applied.
Volume
40
Issue
1 Suppl
First Page
588
Last Page
594
ISSN
0008-543X
Published In/Presented At
Lewis, G. C., Jr, & Blessing, J. (1977). Ovarian cancer: use of multiple modality programs involving surgery, radiation therapy and chemotherapy. Cancer, 40(1 Suppl), 588–594. https://doi.org/10.1002/1097-0142(197707)40:1+<588::aid-cncr2820400725>3.0.co;2-8
Disciplines
Medicine and Health Sciences
PubMedID
406985
Department(s)
Department of Obstetrics and Gynecology
Document Type
Article